kıbrıs ingiltere londra lefkoşa
DOLAR
32,5940
EURO
34,8052
STERLIN
40,6287
BITCOIN
$64.250
Adana Adıyaman Afyon Ağrı Aksaray Amasya Ankara Antalya Ardahan Artvin Aydın Balıkesir Bartın Batman Bayburt Bilecik Bingöl Bitlis Bolu Burdur Bursa Çanakkale Çankırı Çorum Denizli Diyarbakır Düzce Edirne Elazığ Erzincan Erzurum Eskişehir Gaziantep Giresun Gümüşhane Hakkari Hatay Iğdır Isparta İstanbul İzmir K.Maraş Karabük Karaman Kars Kastamonu Kayseri Kırıkkale Kırklareli Kırşehir Kilis Kocaeli Konya Kütahya Malatya Manisa Mardin Mersin Muğla Muş Nevşehir Niğde Ordu Osmaniye Rize Sakarya Samsun Siirt Sinop Sivas Şanlıurfa Şırnak Tekirdağ Tokat Trabzon Tunceli Uşak Van Yalova Yozgat Zonguldak
LONDRA
Hafif yağmur
10°C
LONDRA
10°C
Hafif yağmur
Cumartesi Parçalı az bulutlu
10°C
Pazar Hafif yağmur
="http://www.w3.org/2000/svg" viewBox="0 0 300 300" enable-background="new 0 0 300 300">
11°C
Pazartesi Hafif yağmur
="http://www.w3.org/2000/svg" viewBox="0 0 300 300" enable-background="new 0 0 300 300">
11°C
Salı hafif yağmur
="http://www.w3.org/2000/svg" viewBox="0 0 300 300" enable-background="new 0 0 300 300">
12°C

New hope for sickle cell disease as first new drug in 20 years is approved

New hope for sickle cell disease as first new drug in 20 years is approved
06.10.2021
0
A+
A-

A “revolutionary” life-changing drug treatment for sickle cell disease is to be made available on the NHS – the first new treatment for the disease in 20 years.

It will initially only be made available to around 300 patients but will be extended to 450 in future years after the decision by the National Institute for Health and Care Excellence (Nice), which recommended the drug be available on the NHS.

Sickle cell disease is a serious and lifelong health condition causing severe pain and organ failure often requiring hospital admissions.

The new drug, known as crizanlizumab, will be delivered by a transfusion drip and works by binding to a protein in the blood cells to prevent the restriction of blood and oxygen supply.

It could help as many as 5,000 people over the next three years, the NHS has said. It is hoped the drug will reduce the number of times a sickle cell patient needs to go to A&E by two fifths.

Yorumlar

Henüz yorum yapılmamış. İlk yorumu yukarıdaki form aracılığıyla siz yapabilirsiniz.